Shares of Auris Medical Holding AG (NASDAQ:EARS) saw unusually-strong trading volume on Thursday . Approximately 11,097,396 shares changed hands during mid-day trading, an increase of 1,933% from the previous session’s volume of 545,819 shares.The stock last traded at $0.62 and had previously closed at $0.47.

Separately, Zacks Investment Research upgraded Auris Medical from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research report on Wednesday, August 30th.

The company has a market capitalization of $23.26, a PE ratio of -0.97 and a beta of 0.59. The company has a debt-to-equity ratio of -14.04, a current ratio of 1.86 and a quick ratio of 1.86.

A hedge fund recently bought a new stake in Auris Medical stock. Virtu KCG Holdings LLC bought a new position in Auris Medical Holding AG (NASDAQ:EARS) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned 0.32% of Auris Medical at the end of the most recent reporting period. 25.15% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Auris Medical (EARS) Sees Unusually-High Trading Volume” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at

About Auris Medical

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with's FREE daily email newsletter.